Unlocking Cardiovascular Benefits: Which Patients Profit Most from SGLT2 and GLP-1 Diabetes Medications?
![Unlocking Cardiovascular Benefits: Which Patients Profit Most from SGLT2 and GLP-1 Diabetes Medications?](https://media.post.rvohealth.io/wp-content/uploads/sites/3/2025/02/diabetes-drugs-GettyImages-2164565541-Facebook.jpg)
Recent research sheds light on the effectiveness of newer type 2 diabetes medications, specifically SGLT2 and GLP-1 inhibitors, in reducing the risk of cardiovascular disease. These medications have shown promise in improving cardiovascular health, p ...undefined